Fulgent Genetics Return on Tangible Equity 2015-2025 | FLGT
Current and historical return on tangible equity values for Fulgent Genetics (FLGT) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
| Fulgent Genetics Return On Tangible Equity Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Tangible Equity | Return on Tangible Equity |
| 2025-06-30 | $-0.05B | $0.96B | -5.37% |
| 2025-03-31 | $-0.04B | $0.97B | -4.33% |
| 2024-12-31 | $-0.04B | $0.97B | -4.43% |
| 2024-09-30 | $-0.17B | $0.98B | -17.03% |
| 2024-06-30 | $-0.16B | $0.97B | -16.82% |
| 2024-03-31 | $-0.17B | $0.96B | -17.00% |
| 2023-12-31 | $-0.17B | $0.97B | -17.15% |
| 2023-09-30 | $-0.06B | $0.98B | -6.45% |
| 2023-06-30 | $-0.05B | $0.98B | -4.80% |
| 2023-03-31 | $-0.03B | $0.98B | -2.42% |
| 2022-12-31 | $0.14B | $0.98B | 13.16% |
| 2022-09-30 | $0.27B | $1.07B | 24.29% |
| 2022-06-30 | $0.39B | $1.10B | 36.01% |
| 2022-03-31 | $0.46B | $1.23B | 44.37% |
| 2021-12-31 | $0.51B | $1.08B | 54.46% |
| 2021-09-30 | $0.57B | $0.96B | 70.79% |
| 2021-06-30 | $0.49B | $0.89B | 80.69% |
| 2021-03-31 | $0.42B | $0.80B | 101.40% |
| 2020-12-31 | $0.21B | $0.57B | 92.64% |
| 2020-09-30 | $0.05B | $0.19B | 43.84% |
| 2020-06-30 | $0.00B | $0.09B | 2.61% |
| 2020-03-31 | $0.00B | $0.08B | -1.48% |
| 2019-12-31 | $0.00B | $0.08B | -1.67% |
| 2019-09-30 | $0.00B | $0.06B | -5.80% |
| 2019-06-30 | $-0.01B | $0.05B | -9.76% |
| 2019-03-31 | $-0.01B | $0.05B | -11.59% |
| 2018-12-31 | $-0.01B | $0.05B | -11.43% |
| 2018-09-30 | $-0.01B | $0.05B | -11.27% |
| 2018-06-30 | $-0.01B | $0.05B | -11.16% |
| 2018-03-31 | $-0.01B | $0.05B | -9.17% |
| 2017-12-31 | $0.00B | $0.05B | -5.45% |
| 2017-09-30 | $0.00B | $0.06B | 0.00% |
| 2017-06-30 | $0.00B | $0.06B | 0.00% |
| 2017-03-31 | $-0.01B | $0.06B | -13.51% |
| 2016-12-31 | $-0.01B | $0.05B | -25.81% |
| 2016-06-30 | $-0.01B | $0.02B | -109.09% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Information Systems | $0.651B | $0.283B |
| Fulgent Genetics, Inc. provides genetic testing services to physicians with clinically actionable diagnostic information. The company's technology platform integrates data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory process which serves primarily to hospitals and medical institutions. Fulgent Genetics is headquartered in Temple City, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Veeva Systems (VEEV) | United States | $45.855B | 58.34 |
| Tempus AI (TEM) | United States | $12.818B | 0.00 |
| Doximity (DOCS) | United States | $12.199B | 54.28 |
| Hims & Hers Health (HIMS) | United States | $10.401B | 85.22 |
| IRhythm Technologies (IRTC) | United States | $5.159B | 0.00 |
| Hinge Health (HNGE) | United States | $4.608B | 0.00 |
| Privia Health (PRVA) | United States | $2.610B | 193.36 |
| Inspire Medical Systems (INSP) | United States | $2.596B | 38.16 |
| Heartflow (HTFL) | $2.530B | 0.00 | |
| Phreesia (PHR) | United States | $1.708B | 0.00 |
| Enovis (ENOV) | United States | $1.689B | 8.93 |
| 10x Genomics (TXG) | United States | $1.663B | 0.00 |
| Omnicell (OMCL) | United States | $1.456B | 28.04 |
| Schrodinger (SDGR) | United States | $1.426B | 0.00 |
| Azenta (AZTA) | United States | $1.393B | 60.78 |
| Clover Health Investments (CLOV) | United States | $1.358B | 0.00 |
| Claritev (CTEV) | United States | $1.180B | 0.00 |
| Evolent Health (EVH) | United States | $1.092B | 0.00 |
| Veradigm (MDRX) | United States | $0.498B | 0.00 |
| Zepp Health (ZEPP) | Netherlands | $0.491B | 0.00 |
| Standard BioTools (LAB) | United States | $0.467B | 0.00 |
| Talkspace (TALK) | United States | $0.429B | 128.00 |
| Carlsmed (CARL) | $0.360B | 0.00 | |
| Butterfly Network (BFLY) | United States | $0.360B | 0.00 |
| TruBridge (TBRG) | United States | $0.289B | 50.74 |
| Outset Medical (OM) | United States | $0.236B | 0.00 |
| SOPHiA GENETICS SA (SOPH) | Switzerland | $0.235B | 0.00 |
| Nyxoah SA (NYXH) | Belgium | $0.212B | 0.00 |
| Health Catalyst (HCAT) | United States | $0.205B | 0.00 |
| KORU Medical Systems (KRMD) | United States | $0.193B | 0.00 |
| CapsoVision (CV) | United States | $0.178B | 0.00 |
| MDxHealth SA (MDXH) | Belgium | $0.135B | 0.00 |
| American Well (AMWL) | United States | $0.115B | 0.00 |
| CareCloud (CCLD) | United States | $0.110B | 5.00 |
| EUDA Health Holdings (EUDA) | Singapore | $0.094B | 0.00 |
| ImmunoPrecise Antibodies (IPA) | Canada | $0.092B | 0.00 |
| Insight Molecular Diagnostics (IMDX) | United States | $0.069B | 0.00 |
| Pulmonx (LUNG) | United States | $0.064B | 0.00 |
| 111 (YI) | China | $0.058B | 0.00 |
| P3 Health Partners (PIII) | United States | $0.049B | 0.00 |
| HeartBeam (BEAT) | United States | $0.035B | 0.00 |
| Precipio (PRPO) | United States | $0.024B | 0.00 |
| Healthcare Triangle (HCTI) | United States | $0.023B | 0.00 |
| Zhongchao (ZCMD) | China | $0.023B | 0.00 |
| Bullfrog AI Holdings (BFRG) | United States | $0.013B | 0.00 |
| Predictive Oncology (POAI) | United States | $0.009B | 0.00 |
| HeartSciences (HSCS) | United States | $0.008B | 0.00 |
| Strata Skin Sciences (SSKN) | United States | $0.008B | 0.00 |
| Mobile-health Network Solutions (MNDR) | Singapore | $0.006B | 0.00 |
| MSP Recovery (MSPR) | United States | $0.005B | 0.00 |
| Tivic Health Systems (TIVC) | United States | $0.004B | 0.00 |
| Movano (MOVE) | United States | $0.004B | 0.00 |
| Evaxion - (EVAX) | Denmark | $0.004B | 0.00 |
| PROFUSA (PFSA) | United States | $0.003B | 0.00 |
| Future Health ESG (FHLT) | United States | $0.000B | 0.00 |